Monica Sandhu, MD
Dermatology · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 14
- 2 carriers
- Office
- 1
Offices
1 location · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Plans that list them
14 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Sandhu’s office at (415) 600-1020 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
14 of 14 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Sutter Advantage +More (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A137859 · Current
Licensed to practise in California · since 2015 · expires 2027-07-31 · Harvard Medical School.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Original Medicare doctor bills
$128,409
Medicare paid this office $128,409 for 428 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 317 | $48,711 | $104 |
| Destruction of skin growth, 1-14 growths | 130 | $17,343 | $111 |
| Destruction of precancer skin growth, 1 growth | 185 | $13,868 | $50 |
| Short return visit (20+ min) | 151 | $12,870 | $71 |
| Biopsy of related skin growth, first growth | 95 | $9,811 | $90 |
See all 10 services
| Return visit (30+ min) | 317 | $48,711 | $104 |
| Destruction of skin growth, 1-14 growths | 130 | $17,343 | $111 |
| Destruction of precancer skin growth, 1 growth | 185 | $13,868 | $50 |
| Short return visit (20+ min) | 151 | $12,870 | $71 |
| Biopsy of related skin growth, first growth | 95 | $9,811 | $90 |
| Destruction of precancer skin growth, 2-14 growths | 142 | $5,198 | $7 |
| Short return visit | 32 | $1,854 | $53 |
| New patient visit (45+ min) | 13 | $1,529 | $118 |
| New patient visit (30+ min) | 16 | $1,284 | $80 |
| Biopsy of related skin growth, each additional growth | 17 | $1,048 | $52 |
Procedures Medicare counted
| Melanoma (skin cancer) excision | 20 | More than 74% of doctors who do this |
| Removal of skin lesions | 705 | More than 90% of doctors who do this |
| Removal or shaving of skin growth | 11 | More than 65% of doctors who do this |
| Skin biopsy | 210 | More than 86% of doctors who do this |
Who their Medicare patients are
428 Original Medicare patients in 2024. Average age 76 · Women 64% · Also on Medicaid 4% · Health risk score 0.78. At or below the middle of the specialty; the typical dermatology clinician is at 1.01.
Conditions among them: High blood pressure 54% · Coronary heart disease 21% · Cancer 16% · Atrial fibrillation 14% · Diabetes 12% · Depression 12% · Chronic kidney disease 10% · Heart failure 5% · COPD 4% · Dementia 3%.
The office billed $473,699, Medicare allowed $183,877 and paid $128,409; for 2,156 services of 43 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 428 | 2,156 | 76 | 0.78 | $473,699 | $128,409 |
| 2023 | 478 | 2,310 | 76 | 0.74 | $535,643 | $152,927 |
| 2022 | 344 | 2,420 | 76 | 0.77 | $448,657 | $136,514 |
| 2021 | 373 | 2,399 | 77 | 0.80 | $436,394 | $133,688 |
| 2020 | 353 | 2,063 | 76 | 0.94 | $371,738 | $103,183 |
| 2019 | 460 | 1,832 | 76 | 0.91 | $352,478 | $95,369 |
| 2018 | 101 | 198 | 74 | 0.83 | $42,535 | $13,223 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 15 services
| Return visit (30+ min) | 293 | $47,254 | $110 |
| Short return visit (20+ min) | 190 | $16,661 | $74 |
| Destruction of precancer skin growth, 1 growth | 194 | $16,122 | $53 |
| Destruction of skin growth, 1-14 growths | 97 | $14,559 | $114 |
| Biopsy of related skin growth, first growth | 109 | $12,957 | $94 |
| Destruction of precancer skin growth, 2-14 growths | 146 | $5,246 | $7 |
| New patient visit (45+ min) | 34 | $4,802 | $141 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 13 | $4,382 | $313 |
| New patient visit (30+ min) | 49 | $3,881 | $79 |
| Long return visit (40+ min) | 18 | $2,520 | $133 |
| Punch biopsy, first skin growth | 15 | $2,031 | $127 |
| Biopsy of related skin growth, each additional growth | 24 | $1,979 | $52 |
| Application of light to destroy precancer skin growth | 11 | $1,920 | $160 |
| Short return visit | 37 | $1,877 | $47 |
| Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm | 12 | $1,787 | $128 |
2022: 11 services
| Return visit (30+ min) | 212 | $33,694 | $113 |
| Short return visit (20+ min) | 165 | $18,135 | $80 |
| Destruction of precancer skin growth, 1 growth | 173 | $16,069 | $54 |
| Destruction of skin growth, 1-14 growths | 78 | $12,148 | $114 |
| Biopsy of related skin growth, first growth | 77 | $9,437 | $99 |
| Destruction of precancer skin growth, 2-14 growths | 146 | $6,876 | $7 |
| New patient visit (45+ min) | 19 | $2,817 | $148 |
| New patient visit (30+ min) | 26 | $2,400 | $92 |
| Punch biopsy, first skin growth | 13 | $1,774 | $136 |
| Short return visit | 24 | $1,458 | $54 |
| Biopsy of related skin growth, each additional growth | 12 | $867 | $54 |
2021: 10 services
| Return visit (30+ min) | 194 | $30,713 | $112 |
| Short return visit (20+ min) | 178 | $20,699 | $77 |
| Destruction of precancer skin growth, 1 growth | 170 | $15,011 | $53 |
| Destruction of skin growth, 1-14 growths | 71 | $11,013 | $115 |
| Biopsy of related skin growth, first growth | 65 | $8,293 | $102 |
| Destruction of precancer skin growth, 2-14 growths | 141 | $7,006 | $7 |
| New patient visit (30+ min) | 34 | $3,225 | $95 |
| New patient visit (45+ min) | 20 | $2,543 | $127 |
| Biopsy of related skin growth, each additional growth | 15 | $1,183 | $56 |
| Short return visit | 17 | $1,075 | $51 |
2020: 14 services
| Short return visit (20+ min) | 244 | $19,819 | $57 |
| Return visit (30+ min) | 135 | $16,146 | $93 |
| Destruction of precancer skin growth, 1 growth | 181 | $12,024 | $45 |
| Biopsy of related skin growth, first growth | 109 | $11,839 | $90 |
| Destruction of skin growth, 1-14 growths | 74 | $10,011 | $104 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 16 | $5,019 | $314 |
| Destruction of precancer skin growth, 2-14 growths | 145 | $4,683 | $6 |
| Punch biopsy, first skin growth | 28 | $3,503 | $121 |
| New patient visit (30+ min) | 29 | $1,942 | $67 |
| Biopsy of related skin growth, each additional growth | 23 | $1,841 | $56 |
| New patient visit (15+ min) | 14 | $902 | $64 |
| Short return visit | 16 | $733 | $43 |
| Injection into skin growth, 1-7 growths | 11 | $680 | $49 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 11 | $22 | None |
2019: 12 services
| Short return visit (20+ min) | 301 | $25,773 | $62 |
| Destruction of precancer skin growth, 1 growth | 190 | $12,276 | $49 |
| Destruction of skin growth, 1-14 growths | 76 | $10,117 | $103 |
| Biopsy of related skin growth, first growth | 86 | $8,645 | $90 |
| Return visit (30+ min) | 84 | $8,094 | $88 |
| New patient visit (30+ min) | 63 | $5,426 | $86 |
| New patient visit (15+ min) | 58 | $3,145 | $54 |
| Punch biopsy, first skin growth | 22 | $2,835 | $123 |
| Destruction of precancer skin growth, 2-14 growths | 142 | $2,578 | $5 |
| Short return visit | 47 | $2,398 | $40 |
| Biopsy of related skin growth, each additional growth | 18 | $1,123 | $53 |
| Injection into skin growth, 1-7 growths | 11 | $490 | $38 |
2018: 7 services
| Short return visit (20+ min) | 45 | $3,207 | $64 |
| Biopsy of single growth of skin and/or tissue | 20 | $2,056 | $103 |
| Return visit (30+ min) | 16 | $1,734 | $102 |
| New patient visit (15+ min) | 25 | $1,602 | $64 |
| Destruction of skin growth, 1-14 growths | 13 | $1,471 | $113 |
| New patient visit (30+ min) | 15 | $1,350 | $90 |
| Destruction of precancer skin growth, 1 growth | 16 | $845 | $50 |
Medicaid work
$256 in 2019
Medicaid paid $256 for 12 billed services this clinician did in 2019, up to 12 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Short return visit (20+ min) | 12 | $256 |
| 2019 | 12 | 1 | 12 | $256 |
Drugs they prescribed that Part D paid
$169,635
Pharmacies billed $169,635 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 557) in 2024. At or below the middle of the specialty; the typical dermatology clinician is at 0%.
503 generic and 54 brand-name prescriptions · $169,635 in drug cost · 30 antibiotic prescriptions to 18 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Dupixent | 24 | $88,185 | $3,674 |
| Clobetasol Propionate | 38 | $2,033 | $54 |
| Fluorouracil | 25 | $1,841 | $74 |
| Tacrolimus | 12 | $1,426 | $119 |
| Tazarotene | 13 | $1,024 | $79 |
See all 17 drugs
| Dupixent | 24 | $88,185 | $3,674 |
| Clobetasol Propionate | 38 | $2,033 | $54 |
| Fluorouracil | 25 | $1,841 | $74 |
| Tacrolimus | 12 | $1,426 | $119 |
| Tazarotene | 13 | $1,024 | $79 |
| Tretinoin | 14 | $825 | $59 |
| Doxycycline Hyclate | 23 | $709 | $31 |
| Fluocinonide | 24 | $662 | $28 |
| Ketoconazole | 43 | $611 | $14 |
| Minoxidil | 36 | $516 | $14 |
| Valacyclovir | 20 | $503 | $25 |
| Mupirocin | 43 | $332 | $8 |
| Triamcinolone Acetonide | 43 | $250 | $6 |
| Mometasone Furoate | 17 | $229 | $13 |
| Clindamycin Phosphate | 14 | $178 | $13 |
| Hydrocortisone | 16 | $59 | $4 |
| Cephalexin | 12 | $58 | $5 |
Year by year
| 2024 | 557 | 214 | 0% (0) | 10% | $169,635 |
| 2023 | 539 | 238 | 0% (0) | 12% | $182,340 |
| 2022 | 386 | 176 | 0% (0) | None | $101,733 |
| 2021 | 445 | 175 | None | 9% | $73,126 |
| 2020 | 492 | 192 | None | 9% | $33,251 |
| 2019 | 471 | 215 | None | 8% | $57,524 |
| 2018 | 120 | 73 | None | 13% | $7,564 |
| 2017 | 52 | 30 | 0% (0) | None | $4,023 |
| 2015 | 54 | 19 | None | 33% | $12,403 |
| 2014 | 22 | None | None | None | $4,389 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 18 drugs
| Dupixent | 26 | $99,904 | $3,842 |
| Clobetasol Propionate | 39 | $2,694 | $69 |
| Fluorouracil | 25 | $2,398 | $96 |
| Tacrolimus | 13 | $1,865 | $143 |
| Tretinoin | 12 | $1,447 | $121 |
| Doxycycline Hyclate | 17 | $856 | $50 |
| Ketoconazole | 40 | $822 | $21 |
| Metronidazole | 11 | $768 | $70 |
| Triamcinolone Acetonide | 70 | $692 | $10 |
| Fluocinonide | 19 | $683 | $36 |
| Mupirocin | 44 | $535 | $12 |
| Valacyclovir | 27 | $454 | $17 |
| Betamethasone Diprop Augmented | 15 | $378 | $25 |
| Mometasone Furoate | 16 | $327 | $20 |
| Cephalexin | 21 | $190 | $9 |
| Minoxidil | 15 | $172 | $11 |
| Fluconazole | 13 | $164 | $13 |
| Hydrocortisone | 13 | $74 | $6 |
2022: 14 drugs
| Tacrolimus | 14 | $2,455 | $175 |
| Metronidazole | 12 | $2,312 | $193 |
| Fluorouracil | 16 | $1,820 | $114 |
| Doxycycline Hyclate | 20 | $1,005 | $50 |
| Clobetasol Propionate | 17 | $800 | $47 |
| Ketoconazole | 31 | $713 | $23 |
| Fluocinonide | 12 | $700 | $58 |
| Valacyclovir | 11 | $589 | $54 |
| Mometasone Furoate | 23 | $472 | $21 |
| Triamcinolone Acetonide | 43 | $431 | $10 |
| Mupirocin | 38 | $371 | $10 |
| Prednisone | 12 | $100 | $8 |
| Cephalexin | 11 | $82 | $7 |
| Hydrocortisone | 11 | $65 | $6 |
2021: 12 drugs
| Metronidazole | 15 | $2,903 | $194 |
| Clobetasol Propionate | 43 | $2,270 | $53 |
| Doxycycline Hyclate | 22 | $1,493 | $68 |
| Fluocinonide | 24 | $1,198 | $50 |
| Valacyclovir | 18 | $692 | $38 |
| Triamcinolone Acetonide | 58 | $627 | $11 |
| Ketoconazole | 30 | $584 | $19 |
| Mupirocin | 42 | $442 | $11 |
| Mometasone Furoate | 19 | $402 | $21 |
| Econazole Nitrate | 12 | $374 | $31 |
| Hydroxychloroquine Sulfate | 12 | $332 | $28 |
| Hydrocortisone | 14 | $78 | $6 |
2020: 15 drugs
| Metronidazole | 24 | $3,150 | $131 |
| Fluorouracil | 18 | $1,878 | $104 |
| Doxycycline Hyclate | 31 | $1,870 | $60 |
| Clobetasol Emollient | 13 | $1,673 | $129 |
| Clobetasol Propionate | 24 | $1,389 | $58 |
| Ketoconazole | 45 | $1,307 | $29 |
| Triamcinolone Acetonide | 95 | $1,104 | $12 |
| Fluocinonide | 15 | $754 | $50 |
| Mometasone Furoate | 20 | $494 | $25 |
| Betamethasone Diprop Augmented | 17 | $464 | $27 |
| Mupirocin | 41 | $385 | $9 |
| Econazole Nitrate | 13 | $284 | $22 |
| Hydroxychloroquine Sulfate | 11 | $248 | $23 |
| Cephalexin | 11 | $76 | $7 |
| Hydrocortisone | 11 | $55 | $5 |
2019: 14 drugs
| Clobetasol Propionate | 15 | $2,234 | $149 |
| Fluorouracil | 21 | $2,219 | $106 |
| Ketoconazole | 49 | $1,605 | $33 |
| Metronidazole | 12 | $1,399 | $117 |
| Fluocinonide | 30 | $1,356 | $45 |
| Fluocinolone Acetonide | 11 | $992 | $90 |
| Mometasone Furoate | 35 | $813 | $23 |
| Triamcinolone Acetonide | 91 | $742 | $8 |
| Mupirocin | 50 | $470 | $9 |
| Clindamycin Phosphate | 12 | $465 | $39 |
| Doxycycline Hyclate | 13 | $439 | $34 |
| Valacyclovir | 11 | $300 | $27 |
| Betamethasone Diprop Augmented | 11 | $151 | $14 |
| Hydrocortisone | 20 | $120 | $6 |
2018: 2 drugs
| Triamcinolone Acetonide | 30 | $967 | $32 |
| Fluocinonide | 13 | $807 | $62 |
2017: 1 drug
| Triamcinolone Acetonide | 12 | $450 | $37 |
Money from drug and device companies
$551 in 2025
| 2025 | 8 | 28 | None | $551 |
| 2024 | 6 | 7 | None | $253 |
| 2023 | 2 | 2 | None | $50 |
| 2022 | 2 | 3 | None | $80 |
| 2021 | 1 | 1 | None | $26 |
| 2020 | 2 | 2 | None | $35 |
| 2019 | 3 | 5 | None | $89 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Arcutis Biotherapeutics | Zoryve | $179 | 10 payments
|
| Galderma Laboratories L.P. | Nemluvio | $94 | 5 payments
|
| Incyte | Opzelura | $90 | 3 payments
|
| Regeneron Healthcare Solutions | Dupixent | $68 | 4 payments
|
| Organon | Vtama | $46 | 3 payments
|
| Ucb | Bimzelx | $30 | 1 payment
|
See all 28 published payments
| Galderma Laboratories L.P. | Meals · 2025-12-18 | Nemluvio | $14 |
| Amgen | Meals · 2025-12-10 | Otezla | $22 |
| Organon | Meals · 2025-12-05 | Vtama | $9 |
| Regeneron Healthcare Solutions | Meals · 2025-12-04 | Dupixent | $17 |
| Ucb | Meals · 2025-12-02 | Bimzelx | $30 |
| Arcutis Biotherapeutics | Meals · 2025-11-26 | Zoryve | $12 |
| Arcutis Biotherapeutics | Meals · 2025-11-15 | Zoryve | $17 |
| Incyte | Meals · 2025-10-28 | Opzelura | $39 |
| Arcutis Biotherapeutics | Meals · 2025-10-17 | Zoryve | $17 |
| Regeneron Healthcare Solutions | Meals · 2025-10-14 | Dupixent | $14 |
| Incyte | Meals · 2025-10-08 | Opzelura | $22 |
| Arcutis Biotherapeutics | Meals · 2025-10-07 | Zoryve | $21 |
| Arcutis Biotherapeutics | Meals · 2025-09-30 | Zoryve | $5 |
| Organon | Meals · 2025-09-24 | None | $21 |
| Regeneron Healthcare Solutions | Meals · 2025-09-23 | Dupixent | $18 |
| Galderma Laboratories L.P. | Meals · 2025-09-17 | Nemluvio | $20 |
| Galderma Laboratories L.P. | Meals · 2025-09-09 | Nemluvio | $21 |
| Galderma Laboratories L.P. | Meals · 2025-08-21 | Nemluvio | $19 |
| Arcutis Biotherapeutics | Meals · 2025-08-01 | Zoryve | $16 |
| Organon | Meals · 2025-07-11 | Vtama | $15 |
| Incyte | Meals · 2025-06-10 | Opzelura | $30 |
| Arcutis Biotherapeutics | Meals · 2025-05-30 | Zoryve | $21 |
| Pfizer | Meals · 2025-05-26 | Cibinqo | $23 |
| Arcutis Biotherapeutics | Meals · 2025-03-25 | Zoryve | $26 |
| Arcutis Biotherapeutics | Meals · 2025-03-13 | Zoryve | $17 |
| Galderma Laboratories L.P. | Meals · 2025-03-11 | Nemluvio | $21 |
| Regeneron Healthcare Solutions | Meals · 2025-02-18 | Dupixent | $19 |
| Arcutis Biotherapeutics | Meals · 2025-01-24 | Zoryve | $27 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $253
| Sanofi-Aventis U.S. | Dupixent | $100 | 1 payment
|
| Incyte | Opzelura | $47 | 2 payments
|
| Abbvie | Skyrizi | $31 | 1 payment
|
| Genzyme | Dupixent | $28 | 1 payment
|
| Galderma Laboratories L.P. | None | $28 | 1 payment
|
| Regeneron Healthcare Solutions | Dupixent | $19 | 1 payment
|
2023: $50
| Regeneron Healthcare Solutions | Dupixent | $34 | 1 payment
|
| Pfizer | Cibinqo | $15 | 1 payment
|
2022: $80
| Regeneron Healthcare Solutions | Dupixent | $52 | 2 payments
|
| Abbvie | Rinvoq | $28 | 1 payment
|
2021: $26
| AbbVie | Skyrizi | $26 | 1 payment
|
2020: $35
| Novartis Pharmaceuticals | Cosentyx | $20 | 1 payment
|
| Sun Pharmaceutical Industries | Ilumya | $15 | 1 payment
|
2019: $89
| AbbVie | Humira | $37 | 2 payments
|
| Regeneron Healthcare Solutions | Dupixent | $33 | 2 payments
|
| Ortho Dermatologics a division of Bausch Health US | Siliq | $19 | 1 payment
|
Professional record
- NPI
- 1649698614
- Licence
- CA A137859California A137859: Current · expires 2027-07-31
- Trained
- Harvard Medical School, 2014
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207N00000X (207N00000X)
- Mailing address
- 325 Distel Cir, Los Altos, CA, 94022
- NPI first listed
- 2014-04-07
- NPI last updated
- 2020-06-03
- NPI record certified
- 2020-06-03
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 450 Broadway St, Redwood City, CA, 94063